CSIMarket


Eagle Pharmaceuticals inc   (EGRX)
Other Ticker:  
 

Eagle Pharmaceuticals inc

EGRX's Fundamental analysis








Eagle Pharmaceuticals Inc 's sales fell by -12.8 % in II. Quarter 2023 from the same quarter a year ago. Ranking at No. 3131

Major Pharmaceutical Preparations industry recorded deterioration of revenues by -8.1 %

Eagle Pharmaceuticals Inc realized net income compared to net loss a year ago in II. Quarter 2023

More on EGRX's Growth


Eagle Pharmaceuticals Inc
current PE on trailing twelve month basis is below Major Pharmaceutical Preparations industry average.

Eagle Pharmaceuticals Inc realized cash outflow of $ -1.61per share in trailing twelve-month period.
Company
7.22
PE TTM   
Industry
283.76
PE TTM    
Company's Price to Sales ratio is at 0.33.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.8.


More on EGRX's Valuation
 
 Total Debt (Millions $) 70
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 986,785
 Net Income/Employee (TTM) $ 45,778
 Receivable Turnover (TTM) 2.58
 Tangible Book Value (Per Share $) 7.57

Eagle Pharmaceuticals Inc
current PE on trailing twelve month basis is below Major Pharmaceutical Preparations industry average.

Eagle Pharmaceuticals Inc realized cash outflow of $ -1.61per share in trailing twelve-month period.
Company
7.22
PE TTM   
Industry
283.76
PE TTM    
Company's Price to Sales ratio is at 0.33.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.8.

Eagle Pharmaceuticals Inc Price to Book Ratio is at 0.34 lower than Indusry Avg. of 1295.98. and higher than S&P 500 Avg. of -2057.92

More on EGRX's Valuation

  Market Capitalization (Millions $) 85
  Shares Outstanding (Millions) 13
  Employees 261
  Revenues (TTM) (Millions $) 258
  Net Income (TTM) (Millions $) 12
  Cash Flow (TTM) (Millions $) -21
  Capital Exp. (TTM) (Millions $) 0
  Total Debt (Millions $) 70
  Dividend TTM ($) 0 $
  Dividend Yield TTM (%) -
  Revenue/Employee (TTM) $ 986,785
  Net Income/Employee(TTM) $ 45,778
  Receivable Turnover Ratio (TTM) 2.58
  Tangible Book Value (Per Share $) 7.57

  Market Capitalization (Millions $) 85
  Shares Outstanding (Millions) 13
  Employees 261
  Revenues (TTM) (Millions $) 258
  Net Income (TTM) (Millions $) 12
  Cash Flow (TTM) (Millions $) -21
  Capital Exp. (TTM) (Millions $) 0


    EGRX's Profitability Comparisons
Eagle Pharmaceuticals Inc faced margin deterioraten, primarily through cost pressure. Operating Margin fell in II. Quarter 2023 to 15.94 % from 17.76 % in I. Quarter.

Eagle Pharmaceuticals Inc net profit margin of 7.99 % is currently ranking no. 47 in Major Pharmaceutical Preparations industry, ranking no. 119 in Healthcare sector and number 1598 in S&P 500.





  Ratio
   Capital Ratio (MRQ) 2.16
  Total Debt to Equity (MRQ) 0.28
  Tangible Leverage Ratio (MRQ) 1.53
  Asset Turnover Ratio (TTM) 0.68
  Inventory Turnover Ratio (TTM) 1.48



Eagle Pharmaceuticals Inc faced margin deterioraten, primarily through cost pressure. Operating Margin fell in II. Quarter 2023 to 15.94 % from 17.76 % in I. Quarter.

Eagle Pharmaceuticals Inc net profit margin of 7.99 % is currently ranking no. 47 in Major Pharmaceutical Preparations industry, ranking no. 119 in Healthcare sector and number 1598 in S&P 500.

More on EGRX's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com